AbCellera to Participate at Upcoming Investor Conferences in March

Business Wire

02-12

VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

45th Annual TD Cowen Health Care Conference, March 3-5
KeyBanc Capital Markets Healthcare Forum, March 18-19

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211013862/en/

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242
Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2510357147"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510357147\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2510357147?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 05:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2510357147","market":"us","top_or_hot":-1,"title":"AbCellera to Participate at Upcoming Investor Conferences in March","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"339\" src=\"https://s.yimg.com/uu/api/res/1.2/eJNia005BCNXEsuyW.Qu6g--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/dbc640846da86cd22ab49eaf61ed3848\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>VANCOUVER, British Columbia, February 11, 2025</b>--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:</p>\n<ul>\n<li>45th Annual TD Cowen Health Care Conference, March 3-5</li>\n<li>KeyBanc Capital Markets Healthcare Forum, March 18-19</li>\n</ul>\n<p>Visit AbCellera's Investor Relations website for additional information.</p>\n<p><b>About <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc</b>.</p>\n<p>AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20250211013862/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Inquiries </b><br/>Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242<br/>Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005<br/>Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116<br/><br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera to Participate at Upcoming Investor Conferences in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera to Participate at Upcoming Investor Conferences in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-12 05:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:\n\n45th Annual TD Cowen...</p>\n\n<a href=\"https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://finance.yahoo.com/news/abcellera-participate-upcoming-investor-conferences-210500935.html","article_id":"2510357147","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510357147","pubTimestamp":1739307900,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"VANCOUVER, British Columbia, February 11, 2025----AbCellera  today announced that the Company will participate in the following investor conferences:. 45th Annual TD Cowen Health Care Conference, March 3-5. Visit AbCellera's Investor Relations website for additional information.AbCellera  discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.Inquiries Media: Tiffany Chiu; media@abcellera.com, +1724-1242Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1559-9005Investor Relatio","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","BK4535":"淡马锡持仓"},"translate_title":"AbCellera将参加即将于3月份举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"VANCOUVER, British Columbia, February 11, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:\n\n45th Annual TD Cowen Health Care Conference, March 3-5\nKeyBanc Capital Markets Healthcare Forum, March 18-19\n\nVisit AbCellera's Investor Relations website for additional information.\nAbout AbCellera Biologics Inc.\nAbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20250211013862/en/\nContacts\nInquiries Media: Tiffany Chiu; media@abcellera.com, +1(604)724-1242Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}